- Home
- LBRX
LBRX
LB Pharmaceuticals Inc Common Stock
as 10-29-2025 4:00pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 337.7M | IPO Year: | 2025 |
| Target Price: | $46.33 | AVG Volume (30 days): | 149.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -116.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.36 - $20.25 | Next Earning Date: | 11-21-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest LB Pharmaceuticals Inc Common Stock News
LBRX Breaking Stock News: Dive into LBRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
GlobeNewswire
24 days ago
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
Compare LBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LBRX LB Pharmaceuticals Inc Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.